TRANSPOD
22.7.2022 08:02:07 CEST | Business Wire | Press release
TransPod , the startup that is building the world’s leading ultra-high-speed ground transportation system (the TransPod Line ) to disrupt and redefine passenger and cargo transportation, unveiled the FluxJet, an industry-defining innovation that transforms the way we live, work, and travel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005004/en/
Based on groundbreaking innovations in propulsion and fossil-fuel-free clean energy systems, the FluxJet is a fully electric vehicle that is effectively a hybrid between an aircraft and a train. Featuring technological leaps in contactless power transmission and a new field of physics called veillance flux , the FluxJet travels in a protected guideway at over 1000 km/h – faster than a jet and three times as fast as a high-speed train.
The FluxJet will operate exclusively on the TransPod Line, a network system with stations in key locations and major cities, featuring high-frequency departures designed to enable fast, affordable, and safe travel. Most recently, TransPod confirmed $550M US finance and announced the next phase of an $18B US infrastructure project to build the TransPod Line to connect the cities of Calgary and Edmonton in Alberta, Canada. Preliminary construction work, including the environmental impact assessment, has begun. This critical project will create up to 140,000 jobs and add $19.2B to the region’s GDP throughout construction. Once the TransPod Line is in operation, it will cost passengers approximately 44 per cent less than a plane ticket to travel the corridor and reduce CO2 emissions by 636,000 tonnes per year.
“All the hard work over the past few years has led to this milestone moment where talk is becoming a reality. The technology is proven, and we have the confidence of investors, governments, and partners to continue pushing forward to redefine transportation effectively,” said Sebastien Gendron, co-founder and CEO, TransPod.
At TransPod’s unveiling event in Toronto, a scaled-down FluxJet was featured in a live demonstration showing its flight capabilities. The almost 1-tonne FluxJet vehicle demonstrated a take-off, travel, and landing procedure within its guideway. Event and demo footage can be found here .
“This milestone is a major leap forward,” said Ryan Janzen, co-founder and CTO, TransPod. “The FluxJet is at a nexus of scientific research, industrial development, and massive infrastructure to address passengers' needs and reduce our dependence on fossil-fuel-heavy jets and highways.”
“TransPod completely changes the game with ultra high-speed, zero-emission passenger travel and freight transportation between major gateway cities,” said Yung Wu, CEO of MaRS Discovery District. “It is time for bold action from our policymakers, investors, and operators to support the commercialization of made-in-Canada innovations like TransPod, to win in the multi-trillion dollar global innovation economy."
“The FluxJet is a first for Canadian innovation and is the next great infrastructure project to be brought worldwide,” said Janzen. “The TransPod Line is being developed in collaboration with our partners in Europe, USA, and beyond, including universities, research centres, the aerospace industry, architecture, railway, and construction partners.”
TransPod’s FluxJet unveiling was made possible with the support and collaboration of the Building Trades of Alberta , Canada’s Building Trades Unions , Dassault Systèmes , DHL Express , MaRS , Ikos Consulting , REC Architecture , and SADE Engineering .
About TransPod Inc.
TransPod’s goal is to disrupt and redefine commercial transportation between major cities in developed and emerging markets. The startup was founded in 2015 to build the world’s leading tube-transportation system (the TransPod Line ) to connect people, cities, and businesses with high-speed transportation that is affordable and environmentally sustainable. TransPod Inc. is headquartered in Toronto, Canada and has affiliate companies in Alberta, France, and the UAE. Visit www.transpod.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom